Research Paper Volume 13, Issue 23 pp 25365—25376

Anemoside B4 sensitizes human colorectal cancer to fluorouracil-based chemotherapy through src-mediated cell apoptosis


Figure 1. AB4 sensitizes colorectal cancer cells to 5-FU treatment in vitro. (A) HCT116 and HCT116/FU cells were treated with a gradient concentration of 5-FU (0–100 μM), which showed increased cell survival of HCT116/FU cells than parental cells. (B) HCT116/FU cells were treated with 5-FU (20 μM) and different concentration of AB4 (5–50 μM) for 24 or 48 hours. Cell viability was measured by MTT assays. (C, E) HCT116/FU and ACC1805 cells were treated with 25 μM AB4 and a gradient of 5-FU for 48 h. The cell proliferation was analyzed. (D) HCT116/FU cells were treated with AB4 (25 μM) and/ or 5-FU (20 μM) for 5 days. Cell proliferation was examined with MTT assay. (F, G) Colony formation assays were performed with HCT116/FU cells, which showed reduced number of colonies in AB4 treated group (≥25 μM) than vehicle or 5 μM AB4 treated groups. These results represent the average of three independent experiments. Data are shown as means ± SEM. *P < 0.01.